XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2018
Aug. 31, 2017
Aug. 31, 2018
Aug. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss $ (449,671) $ (425,743) $ (859,248) $ (886,959)
Adjustments to reconcile net loss to net cash used in operating activities:        
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph. D.     557,097 648,164
Changes in operating assets and liabilities        
Prepaid expenses     (16,471)  
Retainer       10,000
Accounts payable     53,656 41,068
Accrued liabilities     22,385 43,766
NET CASH USED IN OPERATING ACTIVITIES     (242,581) (143,961)
CASH FLOWS FROM FINANCING ACTIVITIES        
Contribution of capital     242,484 143,734
NET CASH PROVIDED BY FINANCING ACTIVITIES     242,484 143,734
NET DECREASE IN CASH     (97) (227)
CASH AT BEGINNING OF PERIOD     506 731
CASH AT END OF PERIOD $ 409 $ 504 $ 409 $ 504